Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study

Virginia M Miller, Howard N. Hodis, Brian D. Lahr, Kent R Bailey, Muthuvel Jayachandran

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: Little is known regarding the progression of preclinical atherosclerosis upon cessation of menopausal hormone therapy (MHT). This study evaluated changes in carotid artery intima-media thickness (CIMT) in a subgroup of participants during 4 years and 3 years after the Kronos Early Estrogen Prevention Study (KEEPS). METHODS: Of the women enrolled in KEEPS at Mayo Clinic (n = 118), a subset (n = 76) agreed to participate in this follow-up study. KEEPS MHT assignments were placebo (PBO), n = 33; transdermal 17β-estradiol (tE2), n = 23; and oral conjugated equine estrogens group (oCEE), n = 20. CIMT was measured by B-mode ultrasonography. Longitudinal analysis of CIMT was performed using all available data from pre-, on-, and post-treatment periods. RESULTS: At 7 years, median age of participants was 60.2 years; median time since menopause was 8.5 years. The mean difference in rates of increase was significantly greater over the post- than on-treatment period within the oCEE group (0.010 [0.002-0.017] mm/y), but not within the PBO (0.006 [-0.001 to 0.012] mm/y; P = 0.072) or tE2 (0.002 [-0.005 to 0.010] mm/y; P = 0.312) groups. There were, however, no significant treatment differences in the linear trends over those intervals (P = 0.524). CONCLUSIONS: Cessation of MHT at the lower doses and formulations used in KEEPS did not appear to alter the trajectory of CIMT over a 3-year follow-up period. CIMT, however, increased in all groups over the entire 7-year timeframe as expected with age and timing of menopause possibly key contributors.

Original languageEnglish (US)
Pages (from-to)24-31
Number of pages8
JournalMenopause (New York, N.Y.)
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Carotid Intima-Media Thickness
Carotid Arteries
Estrogens
Hormones
Conjugated (USP) Estrogens
Menopause
Therapeutics
Placebos
Estradiol
Ultrasonography
Atherosclerosis

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy : follow-up from the Kronos Early Estrogen Prevention Study. / Miller, Virginia M; Hodis, Howard N.; Lahr, Brian D.; Bailey, Kent R; Jayachandran, Muthuvel.

In: Menopause (New York, N.Y.), Vol. 26, No. 1, 01.01.2019, p. 24-31.

Research output: Contribution to journalArticle

@article{49e353ceda48452e93af83b2d0c28eb1,
title = "Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study",
abstract = "OBJECTIVE: Little is known regarding the progression of preclinical atherosclerosis upon cessation of menopausal hormone therapy (MHT). This study evaluated changes in carotid artery intima-media thickness (CIMT) in a subgroup of participants during 4 years and 3 years after the Kronos Early Estrogen Prevention Study (KEEPS). METHODS: Of the women enrolled in KEEPS at Mayo Clinic (n = 118), a subset (n = 76) agreed to participate in this follow-up study. KEEPS MHT assignments were placebo (PBO), n = 33; transdermal 17β-estradiol (tE2), n = 23; and oral conjugated equine estrogens group (oCEE), n = 20. CIMT was measured by B-mode ultrasonography. Longitudinal analysis of CIMT was performed using all available data from pre-, on-, and post-treatment periods. RESULTS: At 7 years, median age of participants was 60.2 years; median time since menopause was 8.5 years. The mean difference in rates of increase was significantly greater over the post- than on-treatment period within the oCEE group (0.010 [0.002-0.017] mm/y), but not within the PBO (0.006 [-0.001 to 0.012] mm/y; P = 0.072) or tE2 (0.002 [-0.005 to 0.010] mm/y; P = 0.312) groups. There were, however, no significant treatment differences in the linear trends over those intervals (P = 0.524). CONCLUSIONS: Cessation of MHT at the lower doses and formulations used in KEEPS did not appear to alter the trajectory of CIMT over a 3-year follow-up period. CIMT, however, increased in all groups over the entire 7-year timeframe as expected with age and timing of menopause possibly key contributors.",
author = "Miller, {Virginia M} and Hodis, {Howard N.} and Lahr, {Brian D.} and Bailey, {Kent R} and Muthuvel Jayachandran",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/GME.0000000000001167",
language = "English (US)",
volume = "26",
pages = "24--31",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy

T2 - follow-up from the Kronos Early Estrogen Prevention Study

AU - Miller, Virginia M

AU - Hodis, Howard N.

AU - Lahr, Brian D.

AU - Bailey, Kent R

AU - Jayachandran, Muthuvel

PY - 2019/1/1

Y1 - 2019/1/1

N2 - OBJECTIVE: Little is known regarding the progression of preclinical atherosclerosis upon cessation of menopausal hormone therapy (MHT). This study evaluated changes in carotid artery intima-media thickness (CIMT) in a subgroup of participants during 4 years and 3 years after the Kronos Early Estrogen Prevention Study (KEEPS). METHODS: Of the women enrolled in KEEPS at Mayo Clinic (n = 118), a subset (n = 76) agreed to participate in this follow-up study. KEEPS MHT assignments were placebo (PBO), n = 33; transdermal 17β-estradiol (tE2), n = 23; and oral conjugated equine estrogens group (oCEE), n = 20. CIMT was measured by B-mode ultrasonography. Longitudinal analysis of CIMT was performed using all available data from pre-, on-, and post-treatment periods. RESULTS: At 7 years, median age of participants was 60.2 years; median time since menopause was 8.5 years. The mean difference in rates of increase was significantly greater over the post- than on-treatment period within the oCEE group (0.010 [0.002-0.017] mm/y), but not within the PBO (0.006 [-0.001 to 0.012] mm/y; P = 0.072) or tE2 (0.002 [-0.005 to 0.010] mm/y; P = 0.312) groups. There were, however, no significant treatment differences in the linear trends over those intervals (P = 0.524). CONCLUSIONS: Cessation of MHT at the lower doses and formulations used in KEEPS did not appear to alter the trajectory of CIMT over a 3-year follow-up period. CIMT, however, increased in all groups over the entire 7-year timeframe as expected with age and timing of menopause possibly key contributors.

AB - OBJECTIVE: Little is known regarding the progression of preclinical atherosclerosis upon cessation of menopausal hormone therapy (MHT). This study evaluated changes in carotid artery intima-media thickness (CIMT) in a subgroup of participants during 4 years and 3 years after the Kronos Early Estrogen Prevention Study (KEEPS). METHODS: Of the women enrolled in KEEPS at Mayo Clinic (n = 118), a subset (n = 76) agreed to participate in this follow-up study. KEEPS MHT assignments were placebo (PBO), n = 33; transdermal 17β-estradiol (tE2), n = 23; and oral conjugated equine estrogens group (oCEE), n = 20. CIMT was measured by B-mode ultrasonography. Longitudinal analysis of CIMT was performed using all available data from pre-, on-, and post-treatment periods. RESULTS: At 7 years, median age of participants was 60.2 years; median time since menopause was 8.5 years. The mean difference in rates of increase was significantly greater over the post- than on-treatment period within the oCEE group (0.010 [0.002-0.017] mm/y), but not within the PBO (0.006 [-0.001 to 0.012] mm/y; P = 0.072) or tE2 (0.002 [-0.005 to 0.010] mm/y; P = 0.312) groups. There were, however, no significant treatment differences in the linear trends over those intervals (P = 0.524). CONCLUSIONS: Cessation of MHT at the lower doses and formulations used in KEEPS did not appear to alter the trajectory of CIMT over a 3-year follow-up period. CIMT, however, increased in all groups over the entire 7-year timeframe as expected with age and timing of menopause possibly key contributors.

UR - http://www.scopus.com/inward/record.url?scp=85059203582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059203582&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000001167

DO - 10.1097/GME.0000000000001167

M3 - Article

C2 - 30020254

AN - SCOPUS:85059203582

VL - 26

SP - 24

EP - 31

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 1

ER -